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Abstract
Antimicrobial peptides (AMPs) are strongly expressed in lesional skin in psoriasis and play an important role as
proinflammatory ‘‘alarmins’’ in this chronic skin disease. Vitamin D analogs like calcipotriol have antipsoriatic effects and
might mediate this effect by changing AMP expression. In this study, keratinocytes in lesional psoriatic plaques showed
decreased expression of the AMPs b-defensin (HBD) 2 and HBD3 after topical treatment with calcipotriol. At the same time,
calcipotriol normalized the proinflammatory cytokine milieu and decreased interleukin (IL)-17A, IL-17F and IL-8 transcript
abundance in lesional psoriatic skin. In contrast, cathelicidin antimicrobial peptide expression was increased by calcipotriol
while psoriasin expression remained unchanged. In cultured human epidermal keratinocytes the effect of different vitamin
D analogs on the expression of AMPs was further analyzed. All vitamin D analogs tested blocked IL-17A induced HBD2
expression by increasing IkB-a protein and inhibition of NF-kB signaling. At the same time vitamin D analogs induced
cathelicidin through activation of the vitamin D receptor and MEK/ERK signaling. These studies suggest that vitamin D
analogs differentially alter AMP expression in lesional psoriatic skin and cultured keratinocytes. Balancing AMP ‘‘alarmin’’
expression might be a novel goal in treatment of chronic inflammatory skin diseases.
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Introduction
Psoriasis is a chronic inflammatory skin disorder which affects
approximately 2% of the general population. Although the specific
cause for psoriasis is unknown there is strong evidence for a genetic
basis of the disease [1,2]. Furthermore, a large body of evidence
has identified a dysregulated interplay between keratinocytes and
infiltrating immune cells underlying cutaneous inflammation in
psoriasis [3]. Cytokines and other soluble factors such as
antimicrobial peptides (AMPs) secreted by resident or infiltrating
cells are essential elements in this process of cell-cell communi-
cation. Initially, AMPs were characterized as effector molecules of
innate immunity as they provide a first barrier of defence against
microbial pathogens [4]. In the meantime, an array of additional
functions of AMPs has been identified and due to their multiple
functions as activators of adaptive immune responses and
inflammation the term ‘‘alarmins’’ has been introduced [5]. Two
families of AMPs are among the best characterized for their
‘‘alarmin’’ function: the defensins and the cathelicidins.
Recent publications highlight the role of dysregulated expres-
sion of AMPs in the pathogenesis of psoriasis. Human b-defensins
(HBD) and cathelicidin [6], as well as psoriasin and other AMPs
[7–9], are strongly increased in keratinocytes in psoriatic plaques.
In addition, Hollox et al. were able to show that higher genomic
copy numbers of b-defensin genes correlate with an increased risk
to develop psoriasis [1]. Recently it was demonstrated that
cathelicidin peptide LL-37 is able to suppress apoptosis induction
in keratinocytes [10]. Deregulation of apoptosis control is
characteristic for keratinocytes in psoriasis and increased cathe-
licidin in psoriatic plaques could explain this clinical phenotype.
Furthermore, a mechanism was described by which plasmacytoid
dendritic cells (pDCs) sense and respond to self-DNA coupled with
the cathelicidin LL-37, thereby driving autoimmunity in psoriasis
[11]. Thus, as AMPs might play a major role in the pathogenesis
of psoriasis and skin inflammation controlling AMP expression
might offer a novel approach to psoriasis treatment.
The mechanisms of AMP regulation in keratinocytes in psoriasis
are incompletely understood. Recent studies have highlighted a
role for the Th17 cytokines interleukin- (IL-) 17 and IL-22 in
mediating cutaneous skin inflammation in psoriasis [12,13].
Additionally, serum levels of IL-8 and IL-17 were shown to
correlate with severity of the cutaneous disease in psoriasis patients
[14,15]. HBD2 and HBD3 were shown to be regulated by IL-22
via STAT3 activation [16,17] and by IL-17A through JAK and
NF-kB [18,19]. In keratinocytes, human cathelicidin is directly
regulated by 1,25-dihydroxyvitamin D3 (1,25D3) through a
vitamin D3 responsive element (VDRE) in the 59 untranslated
region (UTR) of its gene CAMP [20]. Interestingly, cytokines and
other mediators of skin inflammation do not induce cathelicidin in
keratinocytes in vitro [21]. However, in the presence of 1,25D3
human keratinocytes upregulate cathelicidin expression in re-
sponse to toll-like receptor (TLR) 2 and IL-17 signaling [22,23].
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These observations point out a paradox in the understanding of the
role of cathelicidin in psoriasis pathogenesis: vitamin D analogs like
calcipotriol are very effective in normalizing the skin phenotype when
applied topically to psoriatic skin [24,25]. As vitamin D analogs
activate the vitamin D receptor (VDR) in keratinocytes one would
expect that they also induce cathelicidin. Increased cathelicidin
‘‘alarmin’’ should then aggravate inflammation by binding self-DNA
and activating pDCs. Still, the opposite is true: vitamin D analogs are
a mainstay in the topical treatment of psoriasis.
To date there are no published studies that have assessed the effect
of vitamin D analogs on AMP expression in keratinocytes in psoriasis.
In this trial we analyzed the expression of several AMPs including b-
defensins and cathelicidin in psoriatic plaques before and after
treatment with the vitamin D analog calcipotriol. Treatment with
calcipotriol led to clinical improvement and a decrease in inflamma-
tory parameters such as IL-17A, IL-17F and IL-8 in psoriatic skin. In
parallel, expression levels of HBD2 and HBD3 decreased. In contrast,
cathelicidin was induced in psoriatic skin after treatment with
calcipotriol. These observations were confirmed in vitro: various
vitamin D analogs decreased inflammatory responses in human
keratinocytes and reduced b-defensin expression through inhibition of
Nf-kB activation. In contrast, all vitamin D analogs tested induced
cathelicidin hCAP-18 through activation of the vitamin D receptor
and a modest involvement of MEK/ERK signaling.
Results
Changes in antimicrobial peptide and inflammatory
cytokine expression in psoriatic plaques after treatment
with calcipotriol
The vitamin D analog calcipotriol is widely and successfully used
in the topical treatment of psoriasis [26]. Cutaneous inflammation is
usually normalized within a few days after the onset of therapy.
Nevertheless, the mechanisms and signaling pathways involved in
the effects of calcipotriol are not completely elucidated. The
expression of various AMPs such as cathelicidin hCAP18/LL-37
and b-defensins is increased in psoriatic plaques [7,27]. Beyond their
antimicrobial function AMPs can act as proinflammatory ‘‘alar-
mins’’ and recent data link these peptides directly to psoriasis
pathogenesis. Indeed, expression of cathelicidin, HBD2, HBD3 and
psoriasin were significantly increased in psoriatic plaques (Figure 1A).
At the same time markers of inflammation such as IL-17A, IL-17F
and IL-8 were elevated confirming earlier results [28]. Topical
treatment with calcipotriol decreased cutaneous inflammation as
demonstrated by decreased IL-17A, IL-17F and IL-8 and
significantly lowered HBD2 and HBD3 transcript abundance
(Figure 1B). In contrast, treatment with calcipotriol increased
cathelicidin levels in psoriatic plaques whereas levels of psoriasin
were unchanged (Figure 1B). Analysis of biopsies from lesional and
non-lesional psoriatic skin confirmed significantly elevated levels of
cathelicidin andHBD2 in lesional psoriatic skin compared to healthy
skin (non-psoriatic) from control patients (Fig. 1C). Neither
cathelicidin nor HBD2 mRNA expression was significantly elevated
in non-lesional psoriatic skin vs. healthy (non-psoriatic) skin, but a
trend towards increased expression was observed. The decrease in
HBD2 peptide after calcipotriol treatment was confirmed as
displayed in Figure 1D. Immunofluorescence stainings confirmed
expression of HBD2 and cathelicidin in epidermal keratinocytes in
psoriatic plaques before and after treatment (Figure S1).
Vitamin D analogs block IL-17A induced HBD2 and IL-8
expression in human keratinocytes by inhibiting Nf-kB
The understanding of the crucial role of IL-17A in skin
inflammation in psoriasis is rapidly evolving [28]. Among its multiple
activities IL-17A was recently identified as a very potent inducer of
HBD2 [18]. HBD2 belongs to the b-defensin family and the b-
defensins have been directly linked to psoriasis pathogenesis [1].
Therefore the effect of the vitamin D analogs calcipotriol and
ZK191784 on IL-17A induced HBD2 expression was analyzed in
keratinocytes in vitro. IL-17A strongly induced HBD2 transcript
abundance in NHEK and induction was significantly reduced by
calcipotriol and ZK191784 (Figure 2A). A dose-dependent inhibition
of HBD2 induction was confirmed with increasing concentrations of
calcipotriol (data not shown). At the same time the induction of IL-8
by IL-17A was decreased by calcipotriol (Figure 2B).
Next, we investigated the mechanism behind the antipsoriatic
effect of the vitamin D analogs. HBD2 and IL-8 are both regulated
by Nf-kB signaling in human epithelial cells [18,19]. A negative
regulator of Nf-kB activity is IkB-a which binds to NF-kB subunits
in the cytoplasm preventing Nf-kB translocation to the nucleus
and subsequent gene activation [29]. Upon activation of the Nf-kB
pathway IkB-a is phosphorylated and subsequently degraded
which results in the release of NF-kB subunits [29]. In additional
analysis, the activity of NF-kB was significantly increased after
stimulation with IL-17A in keratinocytes and this effect was
reduced by co-stimulation with calcipotriol or 1,25D3, respectively
(Figure 2C). In another approach, calcipotriol strongly increased
the expression of IkB-a protein in keratinocytes (Figure 2D). As
expected, stimulation with IL-17A resulted in higher levels of
phosphorylated IkB-a and subsequent IkB-a degradation. When
cells were stimulated with the combination of calcipotriol and IL-
17A higher levels of phosphorylated IkB-a were observed
(Figure 2D). Still, in contrast to stimulation with IL-17A alone,
IkB-a was not degraded when cells were stimulated with
calcipotriol and IL-17A which indicates an inhibition of Nf-kB
activation by calcipotriol (Figure 2D).
Vitamin D analogs induce cathelicidin expression in
human keratinocytes
Cathelicidin is another antimicrobial peptide which acts as an
‘‘alarmin’’ in skin. In particular, cathelicidin peptide LL-37 has
been identified as a critical factor for the activation of an
inflammatory cascade in psoriasis [11]. Unexpectedly, despite
clinical improvement and a decrease in inflammatory parameters
after treatment of psoriasis plaques with calcipotriol the expression
of cathelicidin was not decreased but increased (Figure 1B). To
analyze the effect of vitamin D analogs on cathelicidin expression
in vitro a 5 kb fragment of the 59 untranslated region of the human
cathelicidin gene CAMP was transfected in keratinocytes and
transcriptional activity was assayed. All vitamin D analogs
including calcipotriol enhanced cathelicidin promoter activity
(Figure 3A). Dose- and time-dependent induction of cathelicidin
transcript was confirmed in human primary keratinocytes (NHEK)
(Figure 3B and C) and HaCaT keratinocytes (data not shown).
When used at identical concentrations, calcipotriol exerted similar
effects as 1,25D3, the effect of ZK203278 was slightly, the effect of
ZK191784 significantly lower and ZK159222 showed the weakest
induction of all analogs (Figure 3B). Simultaneously, all analogs
tested increased the cathelicidin precursor protein hCAP18 in
NHEK (Figure 3D). Processing of hCAP-18 to active LL-37
peptide could not be detected in our Western blot system.
VDR and the MEK/ERK signaling pathway are involved in
cathelicidin induction by vitamin D analogs
Having confirmed that vitamin D analogs induce cathelicidin
expression underlying signaling pathways were investigated.
1,25D3 increases cathelicidin expression through activation of
VD3 Analogs and AMP/Alarmins
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the vitamin D receptor [30]. To investigate if vitamin D analogs
enhance cathelicidin also through the VDR siRNA experiments to
silence VDR were performed. Silencing of the VDR (Figure 4A,
left panel) significantly reduced the induction of cathelicidin
transcript by ZK191784, ZK203278 or calcipotriol (Figure 4A,
right panel). Similarly, Western blot analysis demonstrated
silencing of VDR protein expression (Figure 4B, middle panel)
which resulted in strongly reduced hCAP18 induction after
stimulation with vitamin D analogs (Figure 4B, upper panel).
MEK/ERK signaling is critically involved in the regulation
of cathelicidin by 1,25D3 in human keratinocytes [23]. To
confirm involvement of MEK/ERK signaling in the induction
of cathelicidin by vitamin D analogs, primary keratinocytes
were transfected with a combination of siRNA oligonucleotides
directed against ERK1 and ERK2 (Figure 4C, left panel).
Compared to cells treated with control siRNA silencing of
ERK1/ERK2 significantly reduced cathelicidin induction by
1,25D3 and its analogs ZK191784 and calcipotriol. Modest
Figure 1. Expression of antimicrobial peptides in psoriatic plaques before and after treatment with vitamin D analogs. 4-mm punch
biopsies from a marker psoriatic plaque were taken from patients (n = 8) before and after treatment with ointment containing the vitamin D analog
calcipotriol (0.005%; applied twice daily for 5 to 7 days). Total mRNA was extracted and transcript levels of cathelicidin, HBD2, HBD3, psoriasin, IL-17A,
IL-17F and IL-8 were analyzed by qPCR. Expression of antimicrobial peptides and markers of inflammation in untreated, lesional skin of psoriasis
patients was normalized to the mean expression of target genes in skin of the healthy (non-psoriatic) controls (n = 7) (A). In (B) the relative changes
of gene expression levels in calcipotriol treated vs. untreated lesional skin of psoriasis patients are displayed. The Y-axis in (A) and (B) is depicted in
Log10 scale (n. s. not significant, *P,0.05, **P,0.01, *** P,0.001; Mann-Whitney test). (C) Punch biopsies from lesional and non-lesional psoriatic
plaque were taken from patients (n = 6). Total mRNA was extracted and transcript levels of cathelicidin (left panel) and HBD2 (right panel)
analyzed by qPCR. Statistical analysis of lesional or non-lesional, respectively, psoriatic skin vs. healthy (non-psoriatic) controls (n = 6) was performed
with Mann-Whitney test, comparison of lesional vs. non-lesional biopsies was performed with Wilcoxon matched pairs test (n. s. not significant,
*P,0.05, **P,0.01). In (D) Western blot analysis using an antibody which detects HBD2 was performed with total protein extracted from biopsies
taken from lesional skin of one representative psoriasis patient before and after treatment with calcipotriol.
doi:10.1371/journal.pone.0006340.g001
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inhibition was observed for induction by ZK203278 (Figure 4C,
right panel).
To analyze whether MEK/ERK signaling is also involved in b-
defensin induction in keratinocytes additional experiments were
performed. In parallel to cathelicidin induction, MEK/ERK
inhibition by the specific MEK1 inhibitor PD98059 significantly
diminished the effect of IL-17A on HBD2 and HBD3 (Figure 5A).
Blocking of MEK/ERK by PD98059 was confirmed by Western
blot using an antibody against phospho-p44/p42 (Figure 5B).
Discussion
Vitamin D analogs are a hallmark in the treatment of psoriasis
but the mechanisms behind their antipsoriatic actions are not
completely understood. AMPs can act as proinflammatory
mediators or ‘‘alarmins’’ and link adaptive and innate immune
responses [4]. Recent studies suggest a role of the defensins and
cathelicidin in the pathogenesis of skin inflammation in psoriasis
[3]. In particular, increased gene copy numbers of the b-defensins
(HBDs) correlate with the risk to develop this disease [1] and
cathelicidin peptide, which is increased in psoriatic skin, induces
an autoinflammatory cascade leading to skin inflammation [11].
As AMPs are directly involved in psoriasis pathogenesis targeting
AMP expression or function might be a promising approach in the
treatment of cutaneous inflammation in psoriasis.
In this study we demonstrate that treatment of lesional psoriatic
skin with the vitamin D analog calcipotriol normalized the
cutaneous phenotype and at the same time changes the AMP
expression profile. Before treatment the levels of various AMPs
were highly elevated in psoriatic plaques compared to healthy skin.
Calcipotriol treatment effectively decreased epidermal prolifera-
tion but at the same time differentially affected AMP expression.
While expression of HBD2 and HBD3 was strongly downregu-
lated by calcipotriol the levels of cathelicidin were increased.
The impact of treatment on the expression of HBD2 peptide in
inflamed skin in psoriatic plaques has only been studied in a few
studies [31]. IL-17A, which is known to be a very potent inducer of
HBD2 [18], is a central cytokine in psoriasis pathogenesis [32] and
correlates with disease severity [14,15]. In this study HBD2 and
HBD3 were increased in untreated psoriatic plaques. At the same
time markers of inflammation such as IL-17A, IL-17F and IL-8
were elevated. Topical treatment with calcipotriol significantly
Figure 2. Induction of HBD2 and IL-8 by IL-17A is decreased by calcipotriol through inhibition of NF-kB signaling. (A) NHEK were
stimulated with IL-17A (10 ng/ml) in the presence or absence of vitamin D analogs calcipotriol or ZK191784 (1028 M). Cells were harvested after 24 h
and HBD2 transcript levels were analyzed by qPCR. In (B) IL-8 transcript expression after stimulation of NHEK with IL-17A (10 ng/ml) in the presence
or absence of calcipotriol (1028 M) is displayed. Data are means6SD of a single experiment performed in triplicate and representative of 2 to 3
independent experiments (**P,0.01, ***P,0.001; Student’s t test). (C) To study involvement of the Nf-kB pathway we performed reporter gene
analyses with an Nf-kB reporter plasmid. 24 h after transfection of HaCaT keratinocytes cells were stimulated with IL-17A (10 ng/ml) in the presence
or absence of calcipotriol or 1,25D3 (1028 M). Luciferase activity was assayed (*P,0.05, **P,0.01; Student’s t test). (D) To further confirm Nf-kB
involvement cells were stimulated with IL-17A (10 ng/ml) in the presence or absence of calcipotriol (1028 M) and harvested after 0, 15 or 30 min.
Western blot analysis using antibodies against phospho-IkB-a and unphosphorylated IkB-a were performed to analyze activation of NF-kB. Staining
for b-actin served as a loading control.
doi:10.1371/journal.pone.0006340.g002
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decreased cutaneous levels of HBD2 and HBD3 as well as IL-17A,
IL-17F and IL-8.
To analyze the underlying mechanism primary human kerati-
nocytes were stimulated with IL-17A which resulted in strong
induction of HBD2 and IL-8. Both genes are regulated by Nf-kB
signaling [18] and the presence of calcipotriol blocked HBD2 and
IL-8 induction by inhibiting Nf-kB activation. In particular, the
presence of calcipotriol increased the level of the Nf-kB inhibitor
protein IkB-a in NHEK and inhibited IL-17A induced IkB-a
degradation. This is in accordance with an earlier study in which
Riis et al. showed that activation of the vitamin D signaling pathway
increases IkB-a expression resulting in decreased NF-kB DNA
binding activity to the IL-8 kB binding sequence [33]. Furthermore,
vitamin D anaolgs inhibited NF-kB promoter activity in keratino-
cytes. Calcipotriol might therefore decrease HBD2 expression in
keratinocytes by two mechanisms: by directly blocking the induction
of HBD2 through inhibition of Nf-kB and by lowering the tissue
levels of IL-17A. Decreased IL-17A expression might be due to
decreased recruitment of circulating, proinflammatory T–cells to
the skin which was observed earlier after treatment of inflamed skin
with vitamin D analogs [34].
Similar to HBD2, cathelicidin antimicrobial peptide has been
suggested to play an important role in psoriasis pathogenesis.
Elevated levels of this AMP in psoriatic plaques have been published
recently [6,35] and autoinflammatory effects of the cathelicidin
peptide LL-37 have been observed in inflamed skin in psoriasis
Figure 3. Vitamin D analogs enhance cathelicidin promoter activity and induce expression in primary human epidermal
keratinocytes. (A) To analyze the effects of vitamin D analogs on the cathelicidin promoter a 5 kb fragment of the 59 UTR of the cathelicidin gene
CAMP was cloned into a luciferase reporter plasmid and transfected into HaCaT keratinocytes. Cells were stimulated with 1,25D3, ZK159222,
ZK191784, ZK203278 and calcipotriol (all at 1027 M) and luciferase activity was assayed (**P,0.01, ***P,0.001; Student’s t test). In (B) primary human
keratinocytes (NHEK) were stimulated with increasing concentrations of vitamin D analogs ZK159222, ZK191784, ZK203278 or calcipotriol (all:
10210 M – 1028 M). Cells were harvested after 24 h and cathelicidin transcript levels were analyzed by qPCR. (C) NHEK were stimulated with vitamin
D analogs ZK191784 and calcipotriol (all at 1028 M) for 0.5, 1 and 4 hours. Again, cathelicidin transcript abundance was analyzed by qPCR. All data are
means6SD of a single experiment performed in triplicate and are representative of 2 to 3 independent experiments. (D) To evaluate cathelicidin
peptide induction NHEK were treated with calcipotriol, 1,25D3, ZK191784, ZK203278 or ZK159222 (all at 1028 M). Cathelicidin hCAP18 protein
expression was analyzed in NHEK lysates by Western blot after 24 hours. Staining for b-actin served as loading control and hCAP18/b-actin ratios
were analyzed using densitometry.
doi:10.1371/journal.pone.0006340.g003
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[5,11]. In addition, cathelicidin inhibits apoptosis in keratinocytes
which could result in the altered phenotype of lesional psoriatic skin
[10]. In the present study strongly elevated levels of cathelicidin in
keratinocytes in psoriatic plaques were confirmed. Unexpectedly
and despite clinical recovery, real-time PCR and immunofluores-
cence demonstrated increased cathelicidin expression in lesional
skin compared to untreated skin after treatment with calcipotriol. At
the same time IL-17F which is important for neutrophil recruitment
was reduced indicating that the induction of cathelicidin was indeed
due to increased keratinocytic expression and not to neutrophilic
tissue infiltration [36].
This inducing effect of vitamin D analogs on cathelicidin
expression was confirmed in cell culture experiments using
primary keratinocytes: Vitamin D analogs such as calcipotriol
induced cathelicidin through activation of the VDR and
subsequent CAMP transcription. Interestingly, only cathelicidin
precursor protein hCAP18 was increased after stimulation with
vitamin D analogs but not active LL-37 peptide. In psoriatic
plaques LL-37 binds self-DNA and activates pDCs to secrete IFN-
a [11]. However, in our study IFN-a expression was not increased
in psoriatic skin after treatment with calcipotriol (data not shown).
Recently, it was also shown that vitamin D3 does not directly
modulate IFN-a production in pDCs in human skin [37]. It might
therefore be possible that the induction of hCAP18 is not
accompanied by an increase of active LL-37 due to a lack of
factors which are required for hCAP18 processing. Further studies
are needed to identify the signaling events involved in controlled
processing of cathelicidin peptides in skin.
Figure 4. VDR and the MEK/ERK signaling pathway are involved in cathelicidin induction by vitamin D analogs. To characterize the
role of the VDR in increased cathelicidin expression after treatment with vitamin D analogs, NHEK were transfected with siRNA to decrease VDR
expression before stimulation with vitamin D analogs ZK191784, ZK203278 and calcipotriol (all at 1028 M). Silencing of VDR was confirmed by qPCR
(A; left panel) and Western blot (B; middle panel). siRNA suppression of VDR significantly reduced the induction of cathelicidin mRNA by all
vitamin D analogs after 24 hours (A; right panel) (*P,0.05, **P,0.01; Student’s t test). In (B; upper panel) the corresponding cathelicidin peptide
hCAP18 expression levels are displayed as observed by Western blot. Staining for a-tubulin served as loading control and cathelicidin hCAP-18/a-
tubulin ratios were analyzed using densitometry. (C) To analyze the role of MEK/ERK signaling in cathelicidin induction NHEK were transfected
simultaneously with two different siRNAs (20 nM) to decrease ERK1 and ERK2 expression before stimulation with 1,25D3 and its analogs ZK191784,
ZK203278 and calcipotriol (all at 1028 M). Silencing of ERK1 and ERK2 was confirmed by qPCR (C; left panel). siRNA suppression of ERK1 and ERK2
resulted in reduced induction of cathelicidin mRNA by vitamin D analogs (C; right panel). Data are means6SD of a single experiment performed in
triplicate and are representative of 2 to 3 independent experiments (*P,0.05, **P,0.01, ***P,0.001; Student’s t test).
doi:10.1371/journal.pone.0006340.g004
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Vitamin D signaling is crucial for the regulation of tissue
homeostasis in the skin but also involved in the regulation of
systemic calcium homeostasis. Treatment of hyperproliferative
disorders such as psoriasis with vitamin D analogs might induce
hypercalcemia even at a therapeutic dosage [38]. Therefore, a
great effort has been made to develop analogs of vitamin D with
similar antipsoriatic but diminished side effects. In the presented
study the vitamin D analogs ZK203278, ZK159222 and
ZK191784 had similar effects on AMP expression as calcipotriol
[39–43]. All analogs tested induced cathelicidin expression via the
VDR and involved the MEK/ERK signaling pathway similar to
active 1,25D3. This effect could be exploited in other skin diseases
such as atopic dermatitis (AD) where cathelicidin AMP induction
is impaired upon skin infection [6,44]. Recently it was shown that
orally administered vitamin D enhances cathelicidin production in
AD patients [45]. Treatment with low calcemic vitamin D analogs
could therefore be used to prevent microbial superinfections in
these patients. However, larger clinical trials addressing this
question are needed to evaluate the efficiency and tolerability of
these compounds.
In conclusion, vitamin D analogs differentially change AMP
expression in keratinocytes in lesional psoriatic skin. As AMPs act
as proinflammatory ‘‘alarmins’’ and play a role in psoriasis
pathogenesis targeting their expression might be beneficial in this
disease. The development of vitamin D analogs with well directed
effects on AMP expression in psoriasis, but also other cutaneous
diseases, might lead to new treatments for those chronic
inflammatory skin diseases.
Materials and Methods
Patients and skin samples
All treatments and sample acquisitions, including skin biopsies,
were approved by the committee on investigations involving
human subjects at the Faculty of Medicine, University of Munich,
Germany. For all procedures, informed written consent was
obtained. Patients did not receive topical treatment before
entering the study. 4-mm punch biopsies were taken from a
marker psoriatic plaque before treatment with a calcipotriol
containing ointment (0.005%; applied twice daily) and 5 to 7 days
after treatment (n = 8). Skin biopsies from healthy (non-psoriatic)
volunteers (n = 7) served as controls. Additionally, biopsies from
untreated lesional and non-lesional skin from psoriasis patients
(n = 6) were collected. All biopsies were directly transferred to 1 ml
TrizolH (Invitrogen) or cut and one half transferred to 1 ml TrizolH
and the other half to 200 ml RIPA-buffer (10 mM Tris-Cl, 1 mM
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
140 mM NaCl, 1 mM PMSF). All samples were homogenized and
mRNA or total protein extraction was performed and analyzed as
described below.
Cell culture and stimuli
Normal human epidermal keratinocytes (NHEK) were grown in
EpiLifeH cell culture medium (Cascade Biologics) containing
0.06 mM calcium and 1 x EpiLifeH defined growth supplement
(EDGS) at 37uC under standard tissue culture conditions. Stock
cultures were maintained for up to six passages in this medium
with the addition of 10 mg/ml gentamicin and 0.25 mg/ml
amphotericin B. HaCaT keratinocytes were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) with 4.5 g/l glucose
supplemented with 10% fetal bovine serum, 50 U/ml penicillin
and 50 mg/ml streptomycin (PAA Laboratories). Cells at 40–60%
confluence were stimulated for different time periods with 1,25-
dihydroxyvitamin D3 (1,25D3) (1028–1027 M; Sigma), calcipo-
triol (10210–1027 M; LEO Pharma), ZK159222 (10210–1027 M;
Bayer Schering), ZK191784 (10210–1027 M; Bayer Schering),
ZK203278 (10210–1027 M; Bayer Schering) and/or IL-17A
(10 ng/ml; R&D). For inhibition of MEK/ERK the MEK1
inhibitor PD98059 (20 mM; Cell Signaling) was added 1 h before
stimulation.
Figure 5. HBD2 and HBD3 expression is induced by IL-17A via a MEK/ERK-dependent mechanism. (A) To investigate the role of MEK/
ERK signaling in HBD2 and HBD3 expression NHEK were treated with the specific MEK1 inhibitor PD98059 (20 mM) prior to stimulation with IL-17A
(10 ng/ml). Cells were harvested after 24 h and transcript levels were analyzed by qPCR. Inhibition of MEK/ERK significantly blocked HBD2 and HBD3
induction by IL-17A. Data are means6SD of a single experiment performed in triplicate and are representative of 2 to 3 independent experiments
(**P,0.01, ***P,0.001; Student’s t test). The inhibitory effect of PD98059 on MEK/ERK was confirmed by Western blot analyses of phospho-p44/p42
(B, upper panel). Staining for a-tubulin served as loading control.
doi:10.1371/journal.pone.0006340.g005
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Quantitative real-time PCR (qPCR)
Total RNA was extracted from stimulated cells or skin samples
using TrizolH and approximately 1 mg RNA was reverse transcribed
using DyNAmoTM cDNA Synthesis Kit (Finnzymes) according to
the manufacturer’s instructions. The expression of cathelicidin,
HBD2, HBD3, psoriasin, IL-17A, IL-17F, IL-8, VDR, ERK1 and
ERK2 was evaluated using a LightCyclerH 2.0 system and the
corresponding human Universal Probe Library Set (Roche). The
primers were designed by an algorithm on www.universalprobeli-
brary.com and porphobilinogen deaminase (PBGD) was used as
housekeeping gene in a duplex qPCR reaction. PBGD was chosen
because PBDG, cathelicidin and HBD2 belong to a low-abundance
class of mRNAs and expression levels in untreated keratinocytes are
low. Preliminary tests verified that expression of PBGD was not
affected upon treatment of NHEK and HaCaT keratinocytes.
Analyzed genes and corresponding primers are listed in Table 1. All
analyses were performed in triplicate from two to three independent
cell stimulation experiments. Fold induction relative to the vehicle
treated control was calculated as previously described [21]. Results
were considered significant when at least a two-fold difference in
expression levels was detected and statistical analysis revealed
P,0.05.
Western blot
NHEK were stimulated with 1,25D3 (1028 M), calcipotriol
(1028 M), ZK159222 (1028 M), ZK191784 (1028 M), ZK203278
(1028 M) and IL-17A (10 ng/ml) for up to 24 h and lysed in
RIPA-buffer. Total protein was measured with the BCA
TM
Protein
Assay Kit (Pierce). Equivalent amounts were separated on a
NuPAGEH 10% Bis-Tris Gel (Invitrogen). After separation,
proteins were blotted onto an Invitrolon
TM
PVDF membrane
(Invitrogen) and blocked in Tris-buffered saline (TBS) diluted 1%
Western Blocking Reagent (Invitrogen) for 1 h at room temper-
ature. Membranes were stained with antibodies detecting
hCAP18/LL-37 (Innovagen), HBD2 (R&D), VDR (R&D),
phospho-p44/p42 MAP Kinase (Cell Signaling), phospho-IkB-a
(Ser32/36) (Cell Signaling), IkB-a (Cell Signaling), a-tubulin
(Biozol) or b-actin (Sigma) overnight and reprobed with respective
HRP-conjugated secondary antibodies (Dako). Stained protein
was visualized using the Amersham ECL Plus
TM
Western blotting
Detection System (GE Healthcare). For analyses of p44/p42
phosphorylation cells were incubated without addition of EDGS
for 24 h prior to stimulation.
RNAi and transfection
NHEK at about 30% confluence were transfected twice (48 h
apart) with siRNA oligonucleotides using Lipofectamine
TM
RNAi-
MAX Reagent (Invitrogen) to maximize the silencing effect. Cells
were transfected with either a siRNA oligonucleotide against VDR
(20 nM), a mix of siRNA oligonucleotides against ERK1 and
ERK2 (all at 20 nM) or a nontargeted control siRNA oligonucle-
otide (20 nM or 40 nM) and maintained at 37uC under standard
tissue culture conditions. 4 h after the second transfection cells
were stimulated with 1,25D3 (1028 M), calcipotriol (1028 M),
ZK191784 (1028 M) and ZK203278 (1028 M). Keratinocytes
were then harvested and evaluated by qPCR or Western blot.
Reporter gene analysis
To analyze NF-kB promoter activity after stimulation with IL-
17A, calcipotriol and 1,25D3, a fragment of the NF-kB promoter
containing six NF-kB binding sites was cloned into a luciferase
reporter plasmid (pGL3; Promega) and transfected into HaCaT
keratinocytes. To analyze cathelicidin promoter activity after
stimulation with 1,25D3 and its analogs, a 5 kb fragment of the 59
untranslated region (UTR) of the human cathelicidin gene CAMP
was cloned into a luciferase reporter plasmid (pGL4.10; Promega)
and transfected into HaCaT keratinocytes. The 5 kb fragment was
amplified with sense 59 AGAGTCCGAGCTCACAACCTGGA-
GAGGCTGAGTCTG 39 and antisense 59 AGAGTCCCTC-
GAGGGTCCCCATGTCTGCCTCCCTCT 39 primers using
human genomic DNA as a template. Primers were designed to
introduce an XhoI restriction site at the 59 end and a HindIII
restriction site at the 39 end of the amplicon. The amplification
products were digested with XhoI and HindIII and cloned into the
pGL4.10 luciferase reporter vector.
The plasmids were transformed into Escherichia coli DH5a
competent cells, following the manufacturer’s guidelines. After
DNA purification using the Qiagen Midi Plasmid Kit (Qiagen)
and verification of the inserted 5 kb fragment by sequencing
(Eurofins MWG Operon), HaCaT cells were transfected with the
indicated reporter plasmid and the empty pGL4.74 renilla control
vector (Promega). For analysis of the NF-kB promoter activity cells
were stimulated 24 h after transfection with IL-17A (10 ng/ml) in
the presence or absence of calcipotriol or 1,25D3 (all at 1028 M),
and harvested 6 h after stimulation. For analysis of cathelicidin
promoter activity cells were stimulated 4 h after transfection with
1,25D3 (1027 M), calcipotriol (1027), ZK159222 (1027 M),
ZK191784 (1027 M) and ZK203278 (1027 M) for 24 h. Firefly
luciferase activity from the NF-kB pGL3 reporter vector, the
CAMP pGL4.10 reporter vector and renilla luciferase activity
from the pGL4.74 control vector were measured by the Dual-Glo
Luciferase Assay system (Promega) in a luminometer according to
the manufacturer’s instructions. Promoter activity was reported as
the ratio between pGL3 or pGL4.10 and pGL4.74 activities in
each sample.
Immunofluorescence staining
Immunofluorescence stainings were performed to detect
cathelicidin and HBD2 in skin from psoriasis patients before and
after treatment with calcipotriol. Frozen sections of lesional skin
were incubated for 1 h with antibodies detecting hCAP18/LL-37
(Innovagen) and HBD2 (R&D). The sections were then incubated
with NorthernLightsTM fluorescent secondary antibodies (R&D).
Sections were overlayed with ProLong Gold antifade reagent with
DAPI (Invitrogen) and analyzed with a TissueFAXS System
microscope at 100–2006 magnification and the corresponding
HistoQuest software (TissueGnostics).
Table 1. Target genes and corresponding primers for qPCR.
Target Gene Forward Reverse
cathelicidin 59 tcggatgctaacctctaccg 39 59 acaggctttggcgtgtct 39
HBD2 59 tcagccatgagggtcttgta 39 59 ggatcgcctataccaccaaa 39
HBD3 59 tgtttgctttgctcttcctg 39 59cgcctctgactctgcaataa 39
psoriasin 59 aagcctgctgacgatgatg 39 59cgaggtaatttgtgcccttt 39
IL-17A 59 tgggaagacctcattggtgt 39 59 ggatttcgtgggattgtgat 39
IL-17F 59 ggcatcatcaatgaaaacca 39 59 tggggtcccaagtgacag 39
IL-8 59 agacagcagagcacacaagc 39 59 atggttccttccggtggt 39
VDR 59 cttctctggggactcctcct 39 59 tggacgagtccatcatgtct 39
ERK1 59 ccctagcccagacagacatc 39 59 gcacagtgtccattttctaacagt 39
ERK2 59 ccgtgacctcaagccttc 39 59 gccaggccaaagtcacag 39
doi:10.1371/journal.pone.0006340.t001
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Statistical analysis
All statistical analyses were performed using GraphPad Prism
4.0 (GraphPad Software Inc.). Student’s t test or Mann-Whitney
test was used to calculate statistical differences. Analysis of biopsies
from lesional vs. non-lesional psoriatic skin was performed with
Wilcoxon matched pairs test. Values of P,0.05 were considered
significant and all data are displayed as means6SD.
Supporting Information
Figure S1 Expression of HBD2 and cathelicidin in psoriatic
plaques before and after treatment with calcipotriol. Immunoflu-
orescence stainings of tissue sections from a representative patient
demonstrate epithelial localisation of HBD2 and cathelicidin
antimicrobial peptide before and after topical treatment with
calcipotriol in lesional psoriatic skin.
Found at: doi:10.1371/journal.pone.0006340.s001 (0.37 MB
DOC)
Acknowledgments
We thank LEO Pharma for providing us with calcipotriol. We further
thank our colleagues Karin Dietrich, Gerd Gauglitz and Sven Neynaber
for help with the tissue sample acquisition.
Author Contributions
Conceived and designed the experiments: MP SK YD KG EB TR JS.
Performed the experiments: MP SK YD KG EB. Analyzed the data: MP
SK YD KG EB JS. Contributed reagents/materials/analysis tools: AB AS
UZ. Wrote the paper: MP YD TR JS.
References
1. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, et al. (2008) Psoriasis
is associated with increased beta-defensin genomic copy number. Nat Genet 40:
23–25.
2. McCarroll SA (2008) Copy-number analysis goes more than skin deep. Nat
Genet 40: 5–6.
3. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of
psoriasis. Nature 445: 866–873.
4. Schauber J, Gallo RL (2008) Antimicrobial peptides and the skin immune
defense system. J Allergy Clin Immunol 122: 261–266.
5. Oppenheim JJ, Tewary P, de la Rosa G, Yang D (2007) Alarmins initiate host
defense. Adv Exp Med Biol 601: 185–194.
6. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, et al. (2002)
Endogenous antimicrobial peptides and skin infections in atopic dermatitis.
N Engl J Med 347: 1151–1160.
7. Gambichler T, Skrygan M, Tomi NS, Othlinghaus N, Brockmeyer NH, et al.
(2008) Differential mRNA expression of antimicrobial peptides and proteins in
atopic dermatitis as compared to psoriasis vulgaris and healthy skin. Int Arch
Allergy Immunol 147: 17–24.
8. Zheng Y, Niyonsaba F, Ushio H, Ikeda S, Nagaoka I, et al. (2008) Microbicidal
protein psoriasin is a multifunctional modulator of neutrophil activation.
Immunology 124: 357–367.
9. Glaser R, Meyer-Hoffert U, Harder J, Cordes J, Wittersheim M, et al. (2009)
The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis
and after experimental skin barrier disruption. J Invest Dermatol 129: 641–
649.
10. Chamorro CI, Weber G, Gronberg A, Pivarcsi A, Stahle M (2008) The Human
Antimicrobial Peptide LL-37 Suppresses Apoptosis in Keratinocytes. J Invest
Dermatol.
11. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, et al. (2007)
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.
Nature 449: 564–569.
12. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al.
(2007) Development, cytokine profile and function of human interleukin 17-
producing helper T cells. Nat Immunol 8: 950–957.
13. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, et al. (2007) A role
for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp
Immunol 150: 407–415.
14. Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-alpha, IFN-
gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and
correlation with disease severity. Mediators Inflamm 2005. pp 273–279.
15. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, et al. (2009) Serum
levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in
patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:
210–214.
16. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, et al. (2006) IL-22 regulates
the expression of genes responsible for antimicrobial defense, cellular
differentiation, and mobility in keratinocytes: a potential role in psoriasis.
Eur J Immunol 36: 1309–1323.
17. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, et al. (2004) IL-22
increases the innate immunity of tissues. Immunity 21: 241–254.
18. Kao CY, Chen Y, Thai P, Wachi S, Huang F, et al. (2004) IL-17 markedly up-
regulates beta-defensin-2 expression in human airway epithelium via JAK and
NF-kappaB signaling pathways. J Immunol 173: 3482–3491.
19. Kao CY, Kim C, Huang F, Wu R (2008) Requirements for two proximal NF-
kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin
2 expression by conducting airway epithelium. J Biol Chem 283: 15309–15318.
20. Wang T-T, Nestel F, Bourdeau V, Nagai Y, Wang Q, et al. (2004) Cutting Edge:
1,25-Dihydroxyvitamin D3 Is a Direct Inducer of Antimicrobial Peptide Gene
Expression. J Immunol 173: 2909–2912.
21. Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL (2006) Control of
the innate epithelial antimicrobial response is cell-type specific and dependent on
relevant microenvironmental stimuli. Immunology 118: 509–519.
22. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, et al. (2007) Injury
enhances TLR2 function and antimicrobial peptide expression through a
vitamin D-dependent mechanism. J Clin Invest 117: 803–811.
23. Peric M, Koglin S, Kim SM, Morizane S, Besch R, et al. (2008) IL-17A
Enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide
in human keratinocytes. J Immunol 181: 8504–8512.
24. Duweb G, Alhaddar J, Abuhamida M (2005) Calcipotriol solution in scalp
psoriasis. Int J Tissue React 27: 163–166.
25. Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, et al. (2006)
Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert
Opin Pharmacother 7: 597–606.
26. Fogh K, Kragballe K (1997) Vitamin D3 analogues. Clin Dermatol 15:
705–713.
27. Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, et al. (1997)
The expression of the gene coding for the antibacterial peptide LL-37 is induced
in human keratinocytes during inflammatory disorders. J Biol Chem 272:
15258–15263.
28. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC (2007) Interleukin-
17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol 7: 374–381.
29. Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation.
Nat Rev Immunol 8: 837–848.
30. Schauber J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, et al. (2008) Histone
acetylation in keratinocytes enables control of the expression of cathelicidin and
CD14 by 1,25-Dihydroxyvitamin D(3). J Invest Dermatol 128: 816–824.
31. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, et
al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated
with reduced Th17 responses. J Exp Med 204: 3183–3194.
32. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, et al.
(2009) Psoriasis is characterized by accumulation of immunostimulatory and
Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129: 79–88.
33. Riis JL, Johansen C, Gesser B, Moller K, Larsen CG, et al. (2004)
1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured
normal human keratinocytes through an increase in IkappaBalpha expression.
Arch Dermatol Res 296: 195–202.
34. van der Vleuten CJ, de Jong EM, van de Kerkhof PC (1996) Epidermal
differentiation characteristics of the psoriatic plaque during treatment with
calcipotriol. Arch Dermatol Res 288: 366–372.
35. Schittek B, Paulmann M, Senyurek I, Steffen H (2008) The role of antimicrobial
peptides in human skin and in skin infectious diseases. Infect Disord Drug
Targets 8: 135–143.
36. Watanabe H, Kawaguchi M, Fujishima S, Ogura M, Matsukura S, et al. (2009)
Functional characterization of IL-17F as a selective neutrophil attractant in
psoriasis. J Invest Dermatol 129: 650–656.
37. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, et al. (2007)
1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in
myeloid but not plasmacytoid dendritic cells. J Immunol 178: 145–153.
38. Brown AJ, Slatopolsky E (2008) Vitamin D analogs: therapeutic applications and
mechanisms for selectivity. Mol Aspects Med 29: 433–452.
39. Carlberg C (2003) Molecular basis of the selective activity of vitamin D
analogues. J Cell Biochem 88: 274–281.
40. Nijenhuis T, van der Eerden BC, Zugel U, Steinmeyer A, Weinans H, et al.
(2006) The novel vitamin D analog ZK191784 as an intestine-specific vitamin D
antagonist. Faseb J 20: 2171–2173.
41. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, et al. (2006) Vitamin
D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness
to pathogen-associated molecular patterns. Eur J Immunol 36: 361–370.
VD3 Analogs and AMP/Alarmins
PLoS ONE | www.plosone.org 9 July 2009 | Volume 4 | Issue 7 | e6340
42. Toell A, Gonzalez MM, Ruf D, Steinmeyer A, Ishizuka S, et al. (2001) Different
molecular mechanisms of vitamin D(3) receptor antagonists. Mol Pharmacol 59:
1478–1485.
43. Zugel U, Steinmeyer A, Giesen C, Asadullah K (2002) A novel immunosup-
pressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic
activity. J Invest Dermatol 119: 1434–1442.
44. Peric M, Koglin S, Ruzicka T, Schauber J (2009) [Cathelicidins: multifunctional
defense molecules of the skin]. Dtsch Med Wochenschr 134: 35–38.
45. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, et al. (2008) Administration
of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy
Clin Immunol 122: 829–831.
VD3 Analogs and AMP/Alarmins
PLoS ONE | www.plosone.org 10 July 2009 | Volume 4 | Issue 7 | e6340
